{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:30:07Z","timestamp":1785771007626,"version":"3.56.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cilostazol has a vasodilatory function that may be beneficial for patients with vasospastic angina (VSA). We conducted a randomized, open-label, controlled trial to compare the efficacy and safety of long-acting cilostazol and isosorbide mononitrate (ISMN) for VSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study included patients with confirmed VSA between September 2019 and May 2021. Participants were randomly assigned to receive long-acting cilostazol (test group, 200\u2005mg once daily) or conventional ISMN therapy (control group, 20\u2005mg twice daily) for 4\u2005weeks. The clinical efficacy and safety were evaluated using weekly questionnaires.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty patients were enrolled in the study (long-acting cilostazol,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u200520; ISMN,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u200520). Baseline characteristics were balanced between the two groups. Long acting cilostazol showed better angina symptom control within the first week compared to ISMN [reduction of pain intensity score, 6.0 (4.0\u20138.0) vs. 4.0 (1.0\u20135.0),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.005; frequency of angina symptom, 0 (0\u20132.0) vs. 2.0 (0\u20133.0),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.027, respectively]. The rate of neurological adverse reactions was lower in the cilostazol group than in the ISMN group (headache or dizziness, 40 vs. 85%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.009; headache, 30 vs. 70%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-acting cilostazol provided comparable control of angina and fewer adverse neurologic reactions within 4\u2005weeks compared to ISMN. Long-acting cilostazol provides more intensive control of angina within 1\u2005week, suggesting that it may be an initial choice for the treatment of VSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mca.0000000000001366","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T04:03:42Z","timestamp":1712721822000},"page":"459-464","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Long-acting cilostazol versus isosorbide mononitrate for patients with vasospastic angina: a randomized controlled trial"],"prefix":"10.1097","volume":"35","author":[{"given":"Min Gyu","family":"Kang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Hwa","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yong","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Sin","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwhi","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seok","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gyeongsang National University School of Medicine and Cardiovascular Center, Gyeongsang National University Changwon Hospital, Changwon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kook Jin","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June Hong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Ku","family":"Chon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Pusan National University School of Medicine and Cardiology, Cardiovascular Center and Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.jacc.2021.07.053","article-title":"2021 AHA\/ACC\/ASE\/CHEST\/SAEM\/SCCT\/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"78","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes.","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1253\/circj.CJ-66-0098","article-title":"Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013).","volume":"78","year":"2014","journal-title":"Circ J"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jacc.2016.04.050","article-title":"Prognosis of variant angina manifesting as aborted sudden cardiac death.","volume":"68","author":"Ahn","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1253\/circj.CJ-10-0292","article-title":"Prognostic effects of calcium channel blockers in patients with vasospastic angina","volume":"74","author":"Nishigaki","year":"2010","journal-title":"Circ J"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/eurheartj\/ehu313","article-title":"Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association.","volume":"36","author":"Takahashi","year":"2015","journal-title":"Eur Heart J"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.bjp.0701699","article-title":"Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.","volume":"123","author":"Shiraishi","year":"1998","journal-title":"Br J Pharmacol"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2008.12.025","article-title":"Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study.","volume":"53","author":"Jeong","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3390\/jcm9061678","article-title":"Adjunctive cilostazol to dual antiplatelet therapy to enhance mobilization of endothelial progenitor cell in patients with acute myocardial infarction: a randomized, placebo-controlled episode trial.","volume":"9","author":"Park","year":"2020","journal-title":"J Clin Med"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1755-5922.2012.00312.x","article-title":"Efficacy of cilostazol on uncontrolled coronary vasospastic angina: a pilot study.","volume":"31","author":"Yoo","year":"2013","journal-title":"Cardiovasc Ther"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/heartjnl-2014-305986","article-title":"A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina.","volume":"100","author":"Shin","year":"2014","journal-title":"Heart"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5414\/CP203434","article-title":"Pharmacokinetic study of two extended-release formulations of cilostazol in healthy Korean subjects: a randomized, open-label, multiple-dose, two-period crossover study.","volume":"57","author":"Shin","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence.","volume":"17","author":"Vrijens","year":"2015","journal-title":"Europace"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.37.4.378","article-title":"Studies with pain rating scales.","volume":"37","author":"Downie","year":"1978","journal-title":"Ann Rheum Dis"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000370027","article-title":"Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina.","volume":"130","author":"Wu","year":"2015","journal-title":"Cardiology"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0735-1097(99)00259-4","article-title":"Assessment and treatment of endothelial dysfunction in humans.","volume":"34","author":"Anderson","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","article-title":"Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A \u2013 and phosphatidylinositol 3-kinase\/Akt-dependent mechanism.","volume":"189","author":"Hashimoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9149(03)00458-2","article-title":"Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris.","volume":"92","author":"Watanabe","year":"2003","journal-title":"Am J Cardiol"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.5551\/jat.32912","article-title":"The effect of cilostazol on endothelial function as assessed by flow-mediated dilation in patients with coronary artery disease.","volume":"23","author":"Mori","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.clinthera.2011.10.024","article-title":"Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.","volume":"33","author":"Lee","year":"2011","journal-title":"Clin Ther"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"1053867","DOI":"10.3389\/fcvm.2022.1053867","article-title":"Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome.","volume":"9","author":"Kang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R22-20250729","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors.","volume":"72","author":"Gresele","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2020.05.012","article-title":"The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1alpha.","volume":"304","author":"Gomes de Almeida Schirmer","year":"2020","journal-title":"Atherosclerosis"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3390\/cells10081998","article-title":"Inhibition of phosphodiesterase 3A by cilostazol dampens proinflammatory platelet functions.","volume":"10","author":"Coenen","year":"2021","journal-title":"Cells"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jcmg.2015.03.010","article-title":"OCT-defined morphological characteristics of coronary artery spasm sites in vasospastic angina.","volume":"8","author":"Shin","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.recesp.2016.10.027","article-title":"Thrombus and plaque erosion characterized by optical coherence tomography in patients with vasospastic angina.","volume":"70","author":"Shin","year":"2017","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial.","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"R28-20250729","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.","volume":"9","author":"Shinohara","year":"2010","journal-title":"Lancet Neurol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:38:39Z","timestamp":1785767919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0000000000001366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001366","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,9]]}}}